Table 4.
The list of clinical trials performed with the major enzyme/prodrug systems in the past decade. Clinical trials before year 2003 are not shown.
| Enzyme/Prodrug System | Clinical Stage | Tumor Type | Vector | Reference |
|---|---|---|---|---|
| HSVTK/GCV | I/II | Glioblastoma multiform | Liposomal | [70] |
| HSVTK/GCV | I | Prostate cancer | Adenoviral | [71] |
| HSVTK/GCV | I | Head and neck cancer and other malignant tumors | Adenoviral | [73] |
| HSVTK/GCV | I | Prostate cancer | Adenoviral | [82] |
| HSVTK/GCV | I | Hepatocellular carcinoma | Adenoviral | [74] |
| HSVTK/GCV | I | Recurrent Gynecologic Cancer | Adenoviral | [81] |
| CD/5-FC and HSVTK/GCV | I | Prostate cancer | Adenoviral | [98] |
| CD/5-FC and HSVTK/GCV | I | Prostate cancer | Adenoviral | [101] |
| CD/5-FC and HSVTK/GCV | I | Prostate cancer | Adenoviral | [100] |
| NTR/CB1954 | I | Gastrointestinal | Adenoviral | [107] |
| NTR/CB1954 | I | Liver cancer | Adenoviral | [118] |
| NTR/CB1954 | I/II | Prostate cancer | Adenoviral | [113] |
| CPG2/Nitrogen Mustard | I | Colorectal carcinoma | ADEPT | [120] |
| P450/Oxazaphosphorine | I/II | Pancreatic carcinoma | Encapsulated Allogeneic Cells | [128] |
| P450/Oxazaphosphorine | I | Breast cancer or Melanoma | MetXia-P450 (Retroviral) | [129] |